Drug
Tobevibart clinical trials
Also written VIR-3434.
- studies test it
- 6
- open now
- 1
- in phase 3
- 1
- first study started
- 2020
Keep track of what changes. Save the tobevibart studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
6 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 1
Vir Biotechnology, Inc. (4) · Virion Therapeutics (1) · University Health Network, Toronto (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tobevibart is read from its arms, and is right about nine times in ten.
Testing it · 6
- Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]RecruitingPhase 2University Health Network, TorontoNCT06216470Written as VIR-3434
- Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434CompletedPhase 1Vir Biotechnology, Inc.NCT05484206Written as VIR-3434
- Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide TherapyCompletedPhase 1Virion TherapeuticsNCT06070051Written as VIR-3434
- SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.Active, not recruitingPhase 2Vir Biotechnology, Inc.NCT05461170Written as VIR-3434
- A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionActive, not recruitingPhase 3Vir Biotechnology, Inc.NCT06903338Written as Tobevibart
- Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus InfectionCompletedPhase 1Vir Biotechnology, Inc.NCT04423393Written as VIR-3434
Given in every arm · 4 — tobevibart is usual care beside what is tested
- A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideActive, not recruitingPhase 3Vir Biotechnology, Inc.NCT07128550Written as Tobevibart
- Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionCompletedPhase 2Vir Biotechnology, Inc.NCT04856085Written as VIR-3434
- A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B InfectionCompletedPhase 1/2Vir Biotechnology, Inc.NCT05612581Written as VIR-3434
- A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionActive, not recruitingPhase 2Vir Biotechnology, Inc.NCT07142811Written as Tobevibart
Codes
What other systems call tobevibart · ClinicalTrials.gg INT017595
- UNII (FDA) PL93ZHC4L3TOBEVIBARTOne source FDA
- NCI Thesaurus C190476TobevibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PL93ZHC4L3 | TOBEVIBART | One source FDA |
| NCI Thesaurus | C190476 | Tobevibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.